Received Nov 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA MNEXSPIKE)) | MODERNA | UNK | — | IM |
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
hiving; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hiving) in a 75-year-old female patient who received mRNA-1273.251 (Spikevax LP.8.1 PFS) for COVID-19 prophylaxis. The suspect product included Pre-filled Syringe injection for COVID-19 prophylaxis. The non-company product included Influenza vaccine for an unknown indication. Concurrent medical conditions included Soy allergy. On 20-Oct-2025, the patient received dose of mRNA-1273.251 (Spikevax LP.8.1 PFS) (Intramuscular use) 1 dosage form and dose of Influenza vaccine (unknown route) 1 dosage form. On an unknown date, the patient started Pre-filled Syringe (unknown route) at an unspecified dose. In October 2025, the patient experienced URTICARIA (hiving). At the time of the report, URTICARIA (hiving) had not resolved. No concomitant medication was reported. The reporter asked for Moderna's recommendation to treat her hiving following administration of Moderna COVID-19 vaccine on 20-Oct-2025, which she had been continuously experiencing since then up to present. She had a soy allergy and connected the reaction to the Moderna COVID-19 vaccine. The patient's hiving started pretty soon after being administered with the Moderna COVID-19 vaccine but did not clarify when exactly it started. The patient did not experience any additional symptoms/events. No treatment medication was reported.
Soy allergy